O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial
Bradley J. Monk, Takafumi Toita, Xiaohua Wu, Juan Carlos Vázquez Limón, Qi Zhou, R. Tarnawski, Masaki Mandai, Ronnie Shapira‐Frommer, Umesh Mahantshetty, Maria Del Pilar Estevez-Diz, Francisco Ramirez Godinez, Szilvia Varga, M.H. Leiva Gálvez, Jung‐Yun Lee, Yulia Kreynina, Kathryn Howells, Sophie Wildsmith, Hannah Dry, Ana T. Nunes, Jyoti Mayadev
Topics & Concepts
DurvalumabMedicinePlaceboClinical endpointChemoradiotherapyInternal medicineAdverse effectCervical cancerUrologyOncologySurgeryRandomized controlled trialCancerNivolumabPathologyImmunotherapyAlternative medicineEndometrial and Cervical Cancer TreatmentsReproductive System and PregnancyCancer Immunotherapy and Biomarkers